Phaseline

Companies › Harbour BioMed (Guangzhou)

Harbour BioMed (Guangzhou): clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HBM4003 (Porustobart)
Anti-CEACAM5 antibody
CEACAM5Phase 1Solid Tumors–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05167071HBM4003 (Porustobart)Phase 1Solid TumorsOncologySep 2025

Targets

CEACAM5 (1)

Companies with the same targets

Chongqing Precision Biotech Beijing Biotech Merck KGaA A2 Biotherapeutics Roche Bristol-Myers Squibb LaNova Medicines Genmab Kivu Bioscience Fortvita Biologics (USA)Inc.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.